设计,合成和强大的抗癌活动的新型Indole-based Bcl-2 抑制剂的设计,合成和强大的抗癌活性
Ahmed M Almehdi1,2, Sameh S M Soliman3,4, Abdel-Nasser A El-Shorbagi4
1College of Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
International journal of molecular sciences
|October 14, 2023
概括
新的以醇为基础的化合物显示出作为向BCL-2蛋白的抗癌剂的希望. 化合物U2有效抑制癌细胞生长,诱导细胞灭绝,并停止细胞循环,具有有利的安全性.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- B细胞淋巴瘤2 (Bcl-2) 蛋白家族是细胞亡的关键调节者,也是癌症治疗中的重要标.
- 印度衍生物代表了开发新型抗癌剂的多功能支架.
研究的目的:
- 设计,合成和评估一系列新的基于醇的化合物,以检测它们对抗Bcl-2-表达癌细胞系的抗癌潜力.
- 调查最强效化合物的作用机制,包括Bcl-2结合亲和力,细胞循环效应和安全概况.
主要方法:
- 合成基于醇的化合物 (U1-6).
- 使用细胞活力测试 (IC50测定) 对抗MCF-7,MDA-MB-231和A549细胞系的抗癌活性评估.
- Bcl-2抑制试验 (ELISA),细胞周期分析,细胞灭亡试验,分子对接和正常纤维细胞的安全性分析.
主要成果:
- 化合物U1-6表现出强大的抗癌活性,具有亚微分子IC50值.
- 化合物U2和U3表现出最高的疗效,特别是在对抗MCF-7细胞.
- 化合物U2显示显著的Bcl-2抑制 (IC50 = 1.2μM),诱导G1/S阶段细胞周期停止和细胞亡,并具有有利的安全性.
- 分子对接证实了Bcl-2结合部位内U2的稳定相互作用.
结论:
- 化合物U2是一种有前途的BCL-2抑制剂,具有显著的抗癌潜力.
- 这项研究提供了对新型基于醇的抗癌剂的结构-活性关系和分子机制的宝贵见解.
- 需要对U2进行进一步的研究,以使其成为一种向癌症治疗方法.
更多相关视频
07:30A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones
Published on: January 21, 2020
8.2K
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
14.0K
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
